Multimeric E-selectin Antagonists for Inflammatory Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current modulators of selectin-mediated function, such as PSGL-1 protein, fucoidan, and heparin, are unsuitable for drug development due to insufficient activity, toxicity, lack of specificity, and poor ADME characteristics, necessitating the development of potent inhibitors of E-selectin-mediated cell adhesion for treating inflammatory diseases and cancers.
Innovation Solution
Development of highly potent multimeric E-selectin antagonists, including their prodrugs and pharmaceutically acceptable salts, which effectively inhibit the binding of E-selectin to its ligands, offering improved physicochemical, pharmacological, and pharmacokinetic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current modulators of selectin-mediated function (PSGL-1 protein, fucoidan, heparin) are used, then selectin activity can be modulated, but they exhibit insufficient activity, toxicity, lack of specificity, and poor ADME characteristics
Solution Approach 1:
The patent modifies the chemical structure of selectin modulators by changing parameters such as molecular weight, charge density, and carbohydrate composition to improve efficacy while reducing toxicity. The optimized compounds exhibit enhanced selectin binding affinity and improved pharmacokinetic properties compared to natural polysaccharides.
Solution Approach 2:
The invention creates composite structures combining synthetic and natural components, such as sulfated polysaccharides with modified backbones, to achieve both high selectin modulation activity and improved safety profile. These composite materials integrate the advantages of natural polysaccharides with the precision of synthetic chemistry.
2Reliability
If selectin-mediated cell adhesion is enhanced for fighting infection, then immune defense is strengthened, but abnormal adhesion results in tissue damage in pathologies like autoimmune diseases and inflammatory conditions
Solution Approach 1:
The patent develops selectin modulators with localized action at the endothelial cell surface, where they specifically inhibit pathological adhesion without affecting systemic immune function. The compounds concentrate at the site of inflammation to provide local therapeutic effect while preserving overall immune competence.
Solution Approach 2:
Instead of enhancing selectin-mediated adhesion systemically to fight infection, the invention inverts the approach by using selective inhibition at pathological sites to prevent tissue damage, thereby allowing normal immune function to proceed unimpeded while blocking harmful adhesion events.
3Reliability
If glycomimetic compounds are used as selectin modulators, then some show promise for drug development, but most current modulators have poor ADME characteristics and availability issues
Solution Approach 1:
The patent segments the complex polysaccharide structures into smaller, more manageable oligosaccharide units that retain selectin binding activity but exhibit improved pharmacokinetic properties. This segmentation facilitates synthesis, purification, and formulation while maintaining therapeutic efficacy.
Solution Approach 2:
The invention creates simplified copies or analogs of natural selectin-binding carbohydrates that mimic the essential binding features while eliminating the problematic aspects of the original structures. These glycomimetic copies are easier to manufacture and exhibit improved stability and bioavailability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multimeric E-selectin antagonists provide significant potency and improved properties, making them effective in treating and preventing diseases associated with excessive or abnormal cell adhesion, including inflammatory diseases and cancers, by modulating selectin-mediated intercellular adhesion.
Implementation Method 1
The compounds of Formula (I) are useful as inhibitors of E-selectin, and in methods for inhibiting binding of E-selectin to one or more E-selectin ligands
Data Source
AI summary
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, highly potent multimeric E-selectin antagonist are desorbed and pharmaceutical compositions comprising at least one of the same.